David Hastings

David C.
Hastings is currently an Independent Director at SCYNEXIS, Inc. since 2015, an Independent Director at Entasis Therapeutics, Inc. since 2018, an Independent Director at Entasis Therapeutics Holdings, Inc. since 2018, and Chief Financial Officer at Trevi Therapeutics, Inc. starting in 2026.
Former roles include Finance Director at Sumitomo Pharma America, Inc. from 1994 to 1997, Independent Non-Executive Director at Vascular Biogenics Ltd. from 2018 to 2023, Chief Financial Officer & Executive Vice President at Incyte Corp.
from 2012 to 2014, Chief Financial Officer, Treasurer & VP at ArQule, Inc. from 2000 to 2003, Senior Manager at PricewaterhouseCoopers LLP in 1994, Vice President & Controller at Genzyme Corp.
from 1997 to 2000, Treasurer, Chief Financial & Accounting Officer at Unilife Corp.
from 2016 to 2017, and Chief Financial & Accounting Officer at Arbutus Biopharma Corp.
from 2019 to 2025.
Education includes undergraduate studies at the University of Vermont.